OncoMatch

OncoMatch/Clinical Trials/NCT06586242

Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy

Is NCT06586242 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin for esophageal cancer.

Phase 2RecruitingXijing HospitalNCT06586242Data as of Jun 2026Location: China

Treatment: Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatinThis study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with anlotinib hydrochloride and chemotherapy.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin

Cancer type

Esophageal Carcinoma

Disease stage

Required: Stage CT2N1-3M0, CT3N0-3M0, CT4N0-3M0, STAGE II-IVA (TNM)

clinical diagnosis is ct2n1-3m0 or ct3n0-3m0 or ct4n0-3m0, and the TNM stage is stage ii-iva

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Lab requirements

Blood counts

bone marrow function basically normal; significant myelosuppression [excluded]

Kidney function

kidney function basically normal

Liver function

liver function basically normal

Cardiac function

heart function basically normal; exclusion for myocardial ischemia/infarction, arrhythmia, cardiac insufficiency

the investigator assessed that the thyroid, lung, bone marrow, liver, kidney and heart functions were basically normal

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06586242 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage CT2N1-3M0 or CT3N0-3M0 or CT4N0-3M0 or STAGE II-IVA is required.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify